Cymabay Therapeutics, Inc. (CBAY) Is At $10.20 Formed Wedge; TEMPLE HOTELS (TMPHF) Shorts Up By 25%

TEMPLE HOTELS INCORPORATED (OTCMKTS:TMPHF) had an increase of 25% in short interest. TMPHF’s SI was 15,500 shares in January as released by FINRA. Its up 25% from 12,400 shares previously. With 800 avg volume, 19 days are for TEMPLE HOTELS INCORPORATED (OTCMKTS:TMPHF)’s short sellers to cover TMPHF’s short positions. It closed at $2.615 lastly. It is down 0.00% since January 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Cymabay Therapeutics, Inc. (CBAY) formed wedge up with $10.81 target or 6.00% above today’s $10.20 share price. Cymabay Therapeutics, Inc. (CBAY) has $447.41M valuation. The stock increased 0.59% or $0.06 during the last trading session, reaching $10.2. About 612,884 shares traded or 1.22% up from the average. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since January 21, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 EPS, up 56.67% or $0.17 from last year’s $-0.3 per share. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10% EPS growth.

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc has $16.0 highest and $2.25 lowest target. $14.20’s average target is 39.22% above currents $10.2 stock price. Cymabay Therapeutics Inc had 17 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Tuesday, November 28 by Leerink Swann. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Monday, September 11. Piper Jaffray has “Buy” rating and $12.0 target. On Wednesday, January 4 the stock rating was maintained by H.C. Wainwright with “Neutral”. The company was downgraded on Wednesday, June 1 by H.C. Wainwright. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald on Wednesday, October 25. The stock has “Buy” rating by H.C. Wainwright on Tuesday, September 8. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald on Tuesday, September 19. The company was maintained on Wednesday, January 10 by Oppenheimer. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 25 report. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, July 17 by H.C. Wainwright.

Temple Hotels Inc., formerly known as Temple Real Estate Investment Trust, is a real estate investment firm specializing in direct and indirect acquisition of hotel properties and assets, investments in hotel real estate in primary and secondary markets, as well as refinancing of under-leveraged properties in markets across Canada and United States. The company has market cap of $72.66 million. The firm targets a capitalization rate for hotel acquisitions between 9 percent and 12 percent. It currently has negative earnings.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: